Previous 10 | Next 10 |
The CTA authorization for DB-OTO provides approval for the Company to expand its planned Phase 1/2 clinical trial to the U.K. in patients two years of age and younger One-time administration of DB-OTO has resulted in production of otoferlin protein and durable auditory brainstem responses...
Decibel Therapeutics press release ( NASDAQ: DBTX ): Q3 net loss of $16M As of September 30, 2022, cash, cash equivalents and available-for-sale securities were $111.9 million, compared to $162.3 million as of December 31, 2021. For further details see: Decibel T...
- Received FDA Clearance of IND Application for DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss - - Announced Submission of CTAs for DB-OTO in the United Kingdom and Spain - - Expect to Initiate a Phas...
BOSTON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the submission of Clinical Trial Applicatio...
The U.S. Food and Drug Administration (FDA) granted clearance to Decibel Therapeutics' ( NASDAQ: DBTX ) investigational new drug (IND) application for starting a phase 1/2 trial of gene therapy DB-OTO to treat hearing loss in pediatric patients. DB-OTO i...
The IND for DB-OTO provides clearance for the Company to initiate a pediatric Phase 1/2 clinical trial in the U.S. in children and infants, and is part of an international regulatory strategy for clinical development One-time administration of DB-OTO has result...
BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of Kevin F. McLaughlin to its B...
BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Off...
BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the submission of an Investigational New Drug ...
Decibel Therapeutics press release ( NASDAQ: DBTX ): Q2 Net loss of $17.05M As of June 30, 2022, cash, cash equivalents and available-for-sale securities were $125.6 million, compared to $162.3 million as of December 31, 2021. For further details see: Decibel The...
News, Short Squeeze, Breakout and More Instantly...
Decibel Therapeutics Inc. Company Name:
DBTX Stock Symbol:
NASDAQ Market:
Decibel Therapeutics Inc. Website:
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Decibel Therapeutics Inc. (DBTX) is expected to report $-0.61 for Q3 2023
NEW YORK, NY / ACCESSWIRE / August 24, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:A Decibel Therapeutics, Inc. (NASDAQ...